Taipei, 27 March 2025 – REGiMMUNE Limited, a biotech company focused on the regulatory T cell targeting drugs for immunotherapy, today officially announces the termination of its potential merger with Kiji Therapeutics. This decision was made after thorough discussions and mutual agreement, considering strategic adjustments and business objectives.
Kenzo Kosuda, CEO of REGiMMUNE stated: “We appreciated Kiji’s cooperation and shared achievements throughout this potential merger. While this chapter closes, we remain open to other potential collaborations in the future.”
Ends
About REGiMMUNE Limited
REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies by harnessing the power of regulatory T cells (Tregs). REGiMMUNE is creating a pipeline of novel product candidates that either enhance Treg activities for immune diseases or suppress Treg activities for cancer.
Corporate Contact
Wendy Kao
Manager
REGiMMUNE Ltd
+886 2 2555 3377 #511
wendyk@regimmune.com
REGiMMUNE Limited與Kiji Therapeutics正式終止潛在合併協議
2025年2月21日，台北 – 瑞格國際生技，一家專注於免疫療法的調節性T細胞開發商，今日正式宣佈，與Kiji Therapeutics的潛在合併協議正式結束。此決定經過雙方充分討論與協商，並基於策略調整與業務目的的考量。
REGiMMUNE的CEO小須田建三表示：「我們感謝Kiji在潛在合併討論期間的合作與共同成果。雖然合作告一段落，我們仍將維持良好關係，共同期待未來可能的合作機會。」
本文結束
關於瑞格國際生技
瑞格係為專注於自體免疫疾病與癌症，運用調控調節性T細胞(Tregs)，開發創新免疫療法之臨床生技公司。瑞格構建之全新候選藥物組合係藉由調控調節性T細胞活性，用於治療免疫疾病及癌症。
媒體連絡人
瑞格國際生技股份有限公司
高裴汶 (Wendy Kao)
經理
+886 2 2555 3377 #511
wendyk@regimmune.com